The regulation of translation and the control of ribosome biogenesis are essential cellular processes whose impact on cell growth and proliferation is manifested at a number of specific levels. Disruption in one or more of the steps that control protein biosynthesis has been associated with alterations in the regulation of cell growth and cell cycle progression. Consistent with this, tumor suppressors and proto-oncogenes have been found to act on these functions and may therefore regulate malignant progression by affecting the protein synthetic machinery. Although many studies have correlated deregulation of protein biosynthesis with cancer, it remains to be established whether this process is necessary and/or sufficient for neoplastic transformation and metastasis. Oncogene (2004 Oncogene ( ) 23, 3138-3144. doi:10.1038 Keywords: mRNA translation; PTEN; TSC1/2; mTOR; Rheb; eIF4E; prostate cancer; glioblastoma
Ras, an important effector in translation control
The effects of growth factors and hormones (e.g. insulin) on the protein synthetic machinery are mediated by signal transduction cascades, which in turn modulate the specific activity of key translation factors (Figure 1 ). Moreover, growth factors stimulate global protein synthesis by increasing both the rates of translation initiation and elongation as well as by triggering ribosome biogenesis to increase translational capacity (Antonetti et al., 1993) . The activation of growth factor signal transduction pathways is initiated by the binding of the ligand to their tyrosine kinase receptors, leading to the activation of the Ras and PI-3K signaling pathways. Ras signaling activates MAP kinase, specifically Erk1/2, which in turn activates MAP kinaseactivated protein kinase (Mnk)1 and 2, two kinases that mediate eukaryotic initiation factor eIF4E-Ser 209 phosphorylation (Scheper et al., 2001) (Figure 1 ), an apparent critical event in driving increased translation. Consistent with this, increased eIF4E expression alone can transform cells both in vitro and in vivo (LazarisKaratzas et al., 1990; Ruggero and Pandolfi, 2003) , arguing that translational control may be causally related to tumor formation. However eIF4E function, regardless of phosphorylation state, is also tonically inhibited by the 4E binding proteins (4E-BP1, 2 and 3) (Figure 1 ). In turn this inhibition is reversed by mTOR phosphorylation of the 4E-BPs, which is mediated by PI-3K via protein kinase B (PKB/Akt) ( Figure 1 ). Thus eIF4E can act as a convergence point between Ras and Akt signaling in the control of translation (Miron et al., 2001 ). Such a model is supported by the data in glial cells demonstrating that the recruitment of oncogenic mRNAs to ribosomes occurs only with elevated combined Ras and Akt signaling, and not Akt signaling alone, indicating that in the context of elevated Akt signaling additional Ras activity enables the mRNA recruitment to occur (Rajasekhar et al., 2003) . Whether other oncogenic signaling pathways can have a similar effect on the expression and activation of eIF4E, and therefore substitute for Ras activation in this regard is not known. An important goal of current investigation is determining how Ras and Akt activities impact on translational control and to unravel the epistatic role of essential components of the translation regulatory network in Ras and Akt cooperative oncogenesis.
Critical role of PI3-kinase signaling in the control of protein biosynthesis
The activation of PI-3K and the production of the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) from PtdIns(4,5)P2 triggers the recruitment and activation of Akt by the phosphatidylinositol-dependent kinases, PDK1 and PDK2 (Brazil and Hemmings, 2001 ). PtdIns(3,4,5)P3 production is counteracted by the lipid phosphatase PTEN (phosphatase and tensin homologue deleted from chromosome 10) tumor suppressor (reviewed in Di Cristofano and Pandolfi, 2000 ; see following paragraphs; Figure 1 ).
mTOR
Akt activation is thought to result in the phosphorylation and inactivation of the tuberous sclerosis complex (TSC) tumor suppressor (see below), leading to the activation of the mTOR signaling pathway (Figure 1 ). mTOR phosphorylates S6 ribosomal protein kinases (S6K1 and 2) and the 4E-BPs. S6K phosphorylation results in its activation, whereas phosphorylation of 4E-BP disrupts its interaction with eIF4E allowing eIF4E to bind and form a functional initiation complex (Figure 1 ). mTOR is emerging as a critical player in growth factor controlled translation, having been charged with integrating nutrient and energy homeostasis with the mitogenic input. Whether the effects of the TSC tumor suppressor are directly on mTOR or its downstream targets is still controversial. For example, insulin does not cause a change in mTOR kinase activity measured against S6K1 as an in vitro substrate (Dennis et al., 2001) , suggesting that insulin might instead influence the composition and signaling capabilities of factors that are bound to mTOR, such as its recently described binding partners raptor and mLST8, rather than mTOR kinase activity itself (Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002) . In addition, it may be that the TSC tumor suppressor operates downstream of mTOR through an as yet undescribed mechanism (Jaeschke et al., 2002) . Recent identification of the proto-oncogene Rheb (Ras homologue enriched in brain), an effector of TSC tumor suppressor function (Garami et al., 2003; Saucedo et al., 2003; Stocker et al., 2003; Zhang et al., 2003) should aid in delineating these interactions ( Figure 1 and see below) . Growth factors such as insulin also positively regulate nutrient uptake, including glucose and amino acids (Munoz et al., 1995; McDowell et al., 1998; Jefferson and Kimball, 2001) . In particular, branched-chain amino acids, most notably leucine, exert a potent stimulatory effect on protein synthesis, an effect that is in part mediated by mTOR and its downstream effectors, the S6Ks and 4E-BPs Schmelzle and Hall, 2000; Gingras et al., 2001b) (Figure 1 ). In addition, it has been shown recently that mTOR activity is directly controlled by homeostatic levels of ATP (Dennis et al., 2001) as well as phosphatidic acid (Fang et al., 2001) . Thus, mTOR appears to act as a permissive factor mediating protein synthesis according to the level of translational and energy precursors (Dennis et al., 1999 (Dennis et al., , 2001 . Consistent with this model, mTOR and PI-3K have been proposed to regulate autophagy negatively (Blommaart et al., 1995; Shigemitsu et al., 1999; Petiot et al., 2000) , whereas PTEN has been suggested to have a positive effect (Arico et al., 2001) .
TSC and Rheb
Recent reports have demonstrated constitutive activation of the mTOR/S6K1 pathway in cells lacking the TSC tumor suppressor function (Jaeschke et al., 2002; Kenerson et al., 2002; Kwiatkowski et al., 2002) . Human TSC is an autosomal dominant multiorgan disorder caused by germline mutations of the TSC1 or TSC2 genes (encoding hamartin and tuberin proteins, respectively) and characterized by mental retardation and hamartomas in various organs (Gomez et al., 1999) . Interestingly, hamartomatous lesions have also been observed in patients with one of three related autosomal dominant disorders associated with germline PTEN mutations: Cowden disease, Lhermitte-Duclos disease and Bannayan-Zonana syndrome. These syndromes share specific developmental defects, hamartomatous lesions in the colonic mucosa as well as increased susceptibility to cancer (reviewed in Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000) . TSC1 and TSC2 proteins form a heterodimeric functional complex that is inactive in the absence of either protein . The TSC tumor suppressor provides a further link between growth factor, nutrient signaling and the mTOR/S6K/4E-BP pathway (Gao and Pan, 2001; Inoki et al., 2002) . In support of this notion, the overexpression of TSC inhibits nutrient-and growth factorinduced S6K1 activation and 4E-BP1 phosphorylation (Inoki et al., 2002; Jaeschke et al., 2002; Manning et al., 2002) . In contrast, a variant of TSC2, harboring a point mutation in the GTPase-activating domain, a mutation associated with the human disease, has no inhibitory effect on S6K1 activation when overexpressed with TSC1 (Jaeschke et al., 2002) . In addition, recent studies have shown that proto-oncogene Rheb is epistatically dominant to TSC1/2 and that TSC2 is the GTPase for Rheb (Garami et al., 2003; Saucedo et al., 2003; Stocker et al., 2003; Zhang et al., 2003) .
Role of S6K activation and S6 phosphorylation in translation control and tumorigenesis
Accumulating evidence links the activation of PI3K-Akt to the two intracellular events that are regulated by mTOR: phosphorylation of S6K1 and 4E-BP1. However, growth factor stimulation can lead to S6K1 activation via mTOR as well as through mTORindependent PI3K-PDK1 signaling inputs (Pullen and Thomas, 1997) . In addition, neither Ca þ 2 , amino acids nor TPA treatment of cells affect Akt activation despite leading to acute S6K1 activation. Importantly, the activity of S6K1 is markedly upregulated in tumors that carry mutations in PTEN and TSC1/2 (reviewed in Ruggero and Pandolfi, 2003) . Indeed, the overgrowth phenotype in the Drosophila eye caused by the loss of TSC function is totally suppressed in a dS6K-deficient background (Radimerski et al., 2002) . More importantly, reducing dS6K signaling rescues early larval lethality associated with the loss of dTsc1/2 function (Radimerski et al., 2002) , arguing that the S6K1 and 2 are promising targets for the treatment of TSC. A comparison of the S6K1 sequence with that of S6K2 reveals that they are highly homologous, sharing 82% identity in the catalytic, linker and autoinhibitory domains, as well as having all the same critical phosphorylation sites . S6K1 activation proceeds first by the phosphorylation of the S/T-P sites in the autoinhibitory domain by mTOR, which acts to facilitate mTOR phosphorylation of T389, allowing PDK1 to dock on T389 and phosphorylate T229 (Biondi et al., 2001) , resulting in S6K1 activation (Pullen et al., 1998) .
The principal substrate of the S6Ks is the ribosomal protein S6, one of 30 distinct ribosomal proteins, which together with 18S rRNA, constitutes the smaller 40S ribosomal subunit (Wool et al., 1996) . S6 has been localized to the small head region of the 40S subunit, near the mRNA/tRNA binding site, consistent with being one of the few 40S ribosomal proteins that has been crosslinked to 28S rRNA of the larger 60S ribosomal subunit (Volarevic and Thomas, 2001) . The importance of S6 in ribosome function and protein translation is underscored by the conditional deletion of S6 in mice (Volarevic et al., 2000) , which results in a block in ribosome biogenesis and cell cycle progression. The regulation of S6 phosphorylation is made more complex due to the presence of S6K2 (Shima et al., 1998) .
S6 phosphorylation has been hypothesized to be involved in the translation of a specific class of mRNAs, TOP (terminal oligopyrimidine tract in the 5 0 untranslated region (5 0 UTR)) mRNA (Jefferies et al., 1994 (Jefferies et al., , 1997 Terada et al., 1994; ) . However recent studies from MEFs, derived from mice deficient for S6K1
À/À , demonstrate that if these two kinases are implicated there must be parallel pathways involved as well (Pende, in press). The 5 0 TOP class of mRNAs includes most notably ribosomal proteins and elongation factors 1A and 2A (eEF1A1 and eEF1A2). 5 0 TOP mRNAs are regulated at the translation level as they are stored in mRNP particles (inactive translational particles), and shift to actively translating polysomes upon mitogenic stimulation (Meyuhas, 2000) . The proteins encoded by 5 0 TOP genes have been shown to act themselves as proto-oncogenes. As an example, eEF1A2 has been found amplified in primary ovarian tumors and its overexpression is oncogenic in fibroblast cell lines and in xenograft tumor models (Anand et al., 2002) . Therefore, deregulation in 5 0 TOP gene expression may have direct consequences on cancer initiation. Furthermore, given the fact that the majority of known 5 0 TOP genes all code for proteins that can upregulate protein synthesis, a positive feedback loop may exist by which an increase in S6 phosphorylation may result in an upregulation in total protein synthesis in the cell. S6 is phosphorylated when quiescent cells re-enter the cell cycle in response to mitogens (Thomas et al., 1979) . Phosphorylation of S6 has been observed both in vivo, during liver regeneration, as well as in various cell lines (Gressner and Wool, 1974; Kozma and Thomas, 1994) . As S6 phosphorylation levels increase in proportion to protein synthesis levels, it has been proposed that S6 could be an important regulator of cell growth. This has been in part substantiated in Drosophila, as inactivation of the dS6K results in a decrease of body size and a defect in cell growth (Montagne et al., 1999) , whereas ectopic overexpression drives cell growth. Although there is no data to indicate that this phenotype is due to alterations mRNA translation in cancer pathogenesis EC Holland et al in translation of TOP genes, coexpression of S6 phosphorylation site mutants, which cannot be phosphorylated, block the dS6 kinase growth response in the wing (Radimerski and Thomas, unpublished observation) . In addition, it has been speculated that S6 phosphorylation may also act to protect ribosomes from autophagic degradation (Blommaart et al., 1995) , which is concomitantly downregulated as anabolic pathways become induced by growth factors (Seglen and Bohley, 1992; Blommaart et al., 1997) .
Control of translation initiation in human cancer
In numerous cancers, general protein synthesis rates and the expression of several translation components are significantly elevated, supporting the potential importance of translational control in tumor progression (Hershey and Miyamoto, 2000) . The increase in protein synthesis correlates with enhanced formation of the eIF4F initiation complex, which binds to the 5 0 cap structure of eukaryotic mRNAs (Gingras et al., 1999b) . The cap consists of the structure m 7 GpppX (where X is any nucleotide). eIF4F is a trimeric complex comprised of eIF4G, eIF4A and eIF4E (Figure 1) , which mediate the binding of the mRNA to the 43S preinitiation complex to form the 48S initiation complex (Pestova et al., 2001) . eIF4E binds directly to the cap structure and is essential for the viability in yeast (Altmann et al., 1987) . eIF4G is a scaffolding protein, which binds eIF4E and eIF4A and directly interacts with eIF3 of the 43S preinitiation complex (Gingras et al., 1999b) . eIF4A serves as an ATP-dependent helicase. eIF4A functionally interacts with a cofactor, eIF4B, an initiation factor that promotes the binding of mRNA to 40S ribosomes in vitro and promotes ATP-dependent helicase activity of eIF4A (Rozen et al., 1990; Raught et al., 2004) , to unwind secondary structures present within the 5 0 UTRs of certain mRNAs, until the initiator AUG. eIF4E appears to be the limiting factor in eIF4F complex formation (Duncan et al., 1987) and to be highly regulated upon growth factor stimulation (see below). Enhanced protein synthesis in response to mitogens, hormones and growth factors is closely linked to increased eIF4F formation for the translation of a specific subset of mRNAs that contain highly structured (G þ C-rich) 5 0 UTRs (Koromilas et al., 1992) . Increased eIF4F formation is thought to contribute to the unwinding of these mRNAs, facilitating ribosome binding. Many structured mRNAs generally encode for growth-promoting genes including myc, ODC and FGF-2 (van der Velden and .
The activity of eIF4E as part of the eIF4F complex formation is regulated by growth factors through two distinct mechanisms. The first involves phosphorylation by Mnk1 (Waskiewicz et al., 1999) , an event requiring binding of the kinase to the carboxyl-terminus of eIF4G (Pyronnet et al., 1999) . Phosphorylation of eIF4E at serine 209 is important for eIF4E's activity and is thought to play a key role in its ability to promote tumorigenesis (Scheper and Proud, 2002) . The biological importance of eIF4E phosphorylation has been demonstrated in Drosophila (Lachance et al., 2002) , where mutation of eIF4E at the equivalent Ser209Ala, results in a delay in development and smaller flies (Lachance et al., 2002) . The second involves a family of small repressor proteins termed the eIF4E binding proteins (4E-BPs) (Raught et al., 2000b) . The 4E-BPs (4E-BP1, 4E-BP2, 4E-BP3) are small unstructured polypeptides that bind eIF4E, thereby preventing the formation of the eIF4F complex and its binding to the cap. Structural studies indicate that the 4E-BPs behave as molecular mimics of eIF4G by competing for binding to eIF4E (Marcotrigiano et al., 1999) .
The regulation of eIF4E binding to the cap is an important target for potential therapeutic intervention for cancer (Meric and Hunt, 2002; see below) , stemming from the finding that overexpression of eIF4E induces malignant transformation of rodent fibroblasts (LazarisKaratzas et al., 1990; Lazaris-Karatzas et al., 1992) , as well as in vivo the transgenic mouse (Ruggero and and that eIF4E expression is significantly increased in many cancers (De Benedetti and Harris, 1999) . Importantly, the binding of eIF4E by the 4E-BPs partially reverts the eIF4E-induced phenotype (Rousseau et al., 1996) , demonstrating that the 4E-BPs behave as tumor suppressors.
The PI3K-Akt-mTOR signaling pathway intimately links eIF4F complex formation and the 4E-BPs to cancer (Hidalgo and Rowinsky, 2000) . As previously mentioned, mTOR directly phosphorylates the 4E-BPs and S6Ks. Phosphorylatable targets of mTOR also include eIF4G (Raught et al., 2000a) and eIF4B. eIF4B is also a direct target of S6K (Raught et al., 2004) . Since the phosphorylation of S6 by S6K may not be the only mechanism by which the translation of TOP mRNAs is controlled, it may be that S6K1/2 mediate cell growth is also controlled through eIF4B phosphorylation. Furthermore, because inhibition of mTOR by rapamycin and its analogous (effective antitumoral agents, see following paragraphs) reduces the phosphorylation of several translational targets, including eIF4G and eIF4B, it adds further merit to the hypothesis that translational initiation plays a critical role in tumorigenesis (Hershey and Miyamoto, 2000) .
The 4E-BPs are hyperphosphorylated in PTENmutated tumors and phosphorylation is regulated by several extracellular stimuli, particularly growth factors, hormones and stress (Gingras et al., 1999a (Gingras et al., , 2001a . 4E-BP1, the best characterized of the BPs, undergoing phosphorylation in a stepwise manner at T37, T46, S65, T70, S83 and S112. Phosphorylation of S65 and T70 are markedly increased by serum stimulation and inhibited by rapamycin (Gingras et al., 2001a) . Phosphorylation of T70 precedes that of S65 and both events require prior phosphorylation of T37 and T46 (Gingras et al., 2001a) . The biological importance of 4E-BP1 phosphorylation is emphasized by the observation that nonphosphorylatable 4E-BP1 mutants prevent colony formation and activate apoptosis in rodent fibroblasts .
Role of PTEN in tumor suppression and translation control
The PTEN gene is located on chromosome 10q23, a genomic region frequently lost in human cancers. Somatic deletions or mutations of this gene have been identified in a large fraction of tumors, frequently in glioblastomas and prostate cancers, placing PTEN among the most commonly mutated genes in human cancer (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000) . Moreover, it has been reported that primary tumors often show loss or alteration of at least one PTEN allele (e.g. 70% of primary prostate cancers; Gray et al., 1998; Whang et al., 1998) supporting PTEN involvement in tumor progression, while homozygous inactivation of PTEN is generally associated with advanced cancer and metastasis (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000) . However, as dictated by Knudson's 'two-hit' hypothesis, the analysis of cancer samples for mutations in PTEN has been initially performed searching for biallelic inactivation of the gene, which pointed at complete PTEN inactivation as a late event in cancer progression. Thus, the consequence of loss/mutation in one PTEN allele in carcinomas in situ or primary cancers may have been underestimated. It could be postulated that while the loss of one PTEN allele may be playing a key role in tumor initiation, complete loss of PTEN may favor metastatization in advanced cancers. Characterization of tumorigenesis and cooperative oncogenesis in Pten þ /À and Pten hypomorph (Pten hy ) mutant mice by the Pandolfi lab supports this notion and demonstrate that Pten is haploinsufficient in some of the biological functions (Di Cristofano et al., 1998 , 2001 Trotman et al., 2003) .
The discovery that PIP-3 is the main in vivo substrate of PTEN placed this phosphatase into a well-defined pathway. PIP-3 levels are very low in quiescent cells, but rapidly increase upon stimulation by growth factors, through PI3-K activation. The role of PTEN is to keep the levels of PIP-3 low by dephosphorylating it at the D3 position. The loss of PTEN function results in increased PIP-3 levels and subsequent Akt hyperactivation (Stambolic et al., 1998; Di Cristofano et al., 1999 , 2001 Backman et al., 2001; Kwon et al., 2001; Suzuki et al., 2001; Crackower et al., 2002; Li et al., 2002) . This leads to elevated mTOR activity and enhanced phosphorylation of several translational targets (4E-BPs, eIF4G, eIF4B, S6K1). As a consequence, the biological outcomes of PTEN mutations include alterations in cell growth and cell size (Backman et al., 2002) .
The importance of mTOR activation in tumorigenesis driven by PTEN functional loss is underscored by studies with CCI-779 (a rapamycin analogue; see below). PTEN-deficient cancer cell lines are sensitive to pharmacological inhibition of mTOR by CCI-779, and enhanced tumor growth caused by constitutive activation of Akt/mTOR is reversed by CCI-779 treatment (Neshat et al., 2001) . In addition, rapamycin can reduce endometrial atypical hyperplasia in Pten heterozygous mice (Podsypanina et al., 2001) , substantiating the notion that mTOR acts downstream the PTEN-Akt pathway in tumorigenesis.
Finally and crucial to the argument for the importance of translational mechanisms in cancer, protein components of oncogenic pathways are encoded by mRNAs that are regulated at the translational level. Numerous published studies have shown that individual oncogenic mRNAs are translationally regulated (reviewed and tabulated in this issue by Rajasekhar and Holland, Table 2 ). However, in order for such an effect to have oncogenic potential, it must be specific to oncogenic mRNAs and not affect the entire spectrum of mRNAs. The global analysis of mRNAs regulated at the translational level as a function of combined Ras and Akt signaling in glia provides some insight into the specificity and magnitude of this phenomenon. In this study, approximately 5% of mRNAs were differentially recruited to polysomes (threefold or greater: in some cases more than 20-fold). Furthermore, the proteins encoded by these mRNAs are highly enriched in cancer-promoting functions (Rajasekhar et al., 2003) .
Therapeutic implications
The immunosuppressant drug rapamycin, which forms a complex with the immunophilin prolyl isomerase FKBP12, specifically inhibits mTOR kinase activity (Huang and Houghton, 2002) . Rapamycin inhibits the proliferation of several types of mammalian cells, most dramatically B-and T-lymphocytes, and results in G1 arrest (Wicker et al., 1990; Terada et al., 1993) . Owing to its inhibitory effects on lymphocyte proliferation, rapamycin is a potent immunosuppressant and effectively prevents allograft rejection. However, rapamycin has also been extensively characterized as a potential anticancer drug, displaying potent cytostatic effects in several cancer cell lines of various histological origins and, less frequently, marked proapoptotic activity (Huang and Houghton, 2002) . In particular, neuroblastoma and glioblastoma cells are sensitive to rapamycin (Hosoi et al., 1998) . Rapamycin also prevents mitogenstimulated downregulation of p27
Kip1 (Nourse et al., 1994; Luo et al., 1996) , a function that may be of critical relevance in the treatment of prostate cancer (CaP) in view of the role of p27
Kip1 functional loss in CaP in combination with Pten loss (see next paragraph). Indeed, CCI-779 (see below) reverses doxorubicin resistance conferred by PTEN status in prostate cancer cells (Grunwald et al., 2002) , and rapamycin reduces the proliferation rate of human pancreatic cancer cells, which display a constitutively active mTOR-S6K1/4E-BP1 signaling pathway (Grewe et al., 1999) . Owing to some of the side effects of rapamycin, analogues such as CCI-779 (an ester of rapamycin) or RAD001 (an oral available analogue of rapamycin also known as Everolimus) have been developed (Huang and Houghton, 2002) . CCI-779 is currently in Phase III clinical trials in cancer patients in both United States and Europe, and mRNA translation in cancer pathogenesis EC Holland et al RAD001 is currently in Phase I trials for the treatment of TSC syndromes and solid tumors that display PTEN mutations or deficiencies. Indeed, since rapamycin and its analogues affect indirectly cap-dependent translation by inhibiting the phosphorylation of 4E-BPs, eIF4G and eIF4B, it has also been suggested that these proteins may provide even more specific targets for potential chemotherapeutic intervention (Meric and Hunt, 2002) . Thus, the in vivo genetic assessment of the relevance in cancer pathogenesis of each event/component in the translation control network is of paramount importance for the identification of novel druggable targets.
